Yan Lan

2.6k total citations · 1 hit paper
34 papers, 1.8k citations indexed

About

Yan Lan is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Yan Lan has authored 34 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 15 papers in Molecular Biology and 14 papers in Immunology. Recurrent topics in Yan Lan's work include Cancer Immunotherapy and Biomarkers (9 papers), Immunotherapy and Immune Responses (8 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Yan Lan is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Immunotherapy and Immune Responses (8 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Yan Lan collaborates with scholars based in United States, China and Germany. Yan Lan's co-authors include Kin-Ming Lo, Stephen D. Gillies, Helen Sabzevari, Bo Marelli, Guozhong Qin, Yan Liang, Jingli Lü, Chunxiao Xu, Jin Qi and Huakui Yu and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Yan Lan

34 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

2018 405 citations Yan Lan, Dong Zhang et al. Science Translational Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yan Lan United States	19	922	782	624	441	144	34	1.8k
Kodandaram Pillarisetti United States	19	1.1k 1.1×	641 0.8×	748 1.2×	372 0.8×	116 0.8×	37	2.0k
Shilpa Bhatia United States	20	706 0.8×	466 0.6×	478 0.8×	93 0.2×	159 1.1×	47	1.5k
Kalyani Penta United States	15	487 0.5×	271 0.3×	955 1.5×	341 0.8×	109 0.8×	21	1.6k
James A. Torchia United States	13	912 1.0×	1.2k 1.6×	351 0.6×	124 0.3×	75 0.5×	17	1.8k
Tomonori Yaguchi Japan	28	989 1.1×	912 1.2×	687 1.1×	115 0.3×	85 0.6×	70	2.0k
Sharon Yee United States	16	635 0.7×	515 0.7×	1.3k 2.1×	302 0.7×	48 0.3×	22	1.8k
Christian D. Young United States	23	790 0.9×	318 0.4×	1.1k 1.7×	216 0.5×	96 0.7×	52	1.9k
Joseph C. Murray United States	15	1.4k 1.5×	957 1.2×	727 1.2×	169 0.4×	73 0.5×	52	2.6k
Valentina Ciccarone United States	14	641 0.7×	420 0.5×	746 1.2×	517 1.2×	159 1.1×	28	1.5k
Keiji Furuuchi Japan	21	536 0.6×	660 0.8×	840 1.3×	104 0.2×	147 1.0×	48	1.8k

Countries citing papers authored by Yan Lan

Since Specialization

Citations

This map shows the geographic impact of Yan Lan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yan Lan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yan Lan more than expected).

Fields of papers citing papers by Yan Lan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yan Lan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yan Lan. The network helps show where Yan Lan may publish in the future.

Co-authorship network of co-authors of Yan Lan

This figure shows the co-authorship network connecting the top 25 collaborators of Yan Lan. A scholar is included among the top collaborators of Yan Lan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yan Lan. Yan Lan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Newsted, Daniel, et al.. (2024). Blockade of TGF-β and PD-L1 by bintrafusp alfa promotes survival in preclinical ovarian cancer models by promoting T effector and NK cell responses. British Journal of Cancer. 130(12). 2003–2015. 14 indexed citations

Jiang, Feng, Jin Qi, Huakui Yu, et al.. (2023). Effect of extended treatment with IAP inhibitor xevinapant post radiotherapy (RT) on efficacy and the tumor microenvironment (TME) in preclinical models.. Journal of Clinical Oncology. 41(16_suppl). 6027–6027. 2 indexed citations

Li, Lulu, et al.. (2023). Linarin Protects Against CCl4-Induced Acute Liver Injury via Activating Autophagy and Inhibiting the Inflammatory Response: Involving the TLR4/MAPK/Nrf2 Pathway. Drug Design Development and Therapy. Volume 17. 3589–3604. 15 indexed citations

Nickels, Sarah, Cláudia Saraiva, Emanuel Berger, et al.. (2022). Microglia integration into human midbrain organoids leads to increased neuronal maturation and functionality. Glia. 70(7). 1267–1288. 106 indexed citations

Woolaver, Rachel A., Christian D. Young, Sana D. Karam, et al.. (2021). Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGFβ/PD-L1 blockade-treated squamous cell carcinoma. Communications Biology. 4(1). 1005–1005. 18 indexed citations

Gulley, James L., Jeffrey Schlom, Mary Helen Barcellos‐Hoff, et al.. (2021). Dual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatment. Molecular Oncology. 16(11). 2117–2134. 113 indexed citations

Jiang, Feng, Hong Wang, Tsz-Lun Yeung, et al.. (2021). 609 Combining bintrafusp alfa with abituzumab enhances suppression of the TGF-β signaling pathway. SHILAP Revista de lepidopterología. A639–A639. 1 indexed citations

Tan, Suiyi, Jinqing Li, Zhaofeng Li, et al.. (2019). The anti-parasitic drug suramin potently inhibits formation of seminal amyloid fibrils and their interaction with HIV-1. Journal of Biological Chemistry. 294(37). 13740–13754. 5 indexed citations

Lan, Yan, Dong Zhang, Chunxiao Xu, et al.. (2018). Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β. Science Translational Medicine. 10(424). 405 indexed citations breakdown →

10.

Xu, Chunxiao, Yanping Zhang, Alex Rolfe, et al.. (2017). Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models. Clinical Cancer Research. 23(19). 5869–5880. 58 indexed citations

11.

Waight, Jeremy D., Shinji Takai, Bo Marelli, et al.. (2014). Cutting Edge: Epigenetic Regulation of Foxp3 Defines a Stable Population of CD4+ Regulatory T Cells in Tumors from Mice and Humans. The Journal of Immunology. 194(3). 878–882. 47 indexed citations

12.

Liu, Xiufeng, Fan Qiu, Zhipeng Liu, et al.. (2014). Urokinase-type plasminogen activator receptor regulates apoptotic sensitivity of colon cancer HCT116 cell line to TRAIL via JNK-p53 pathway. APOPTOSIS. 19(10). 1532–1544. 9 indexed citations

13.

Lan, Yan & Zichun Hua. (2012). [Construction of stable focal adhesion kinase knockdown cell line and preliminary study of its properties].. PubMed. 47(9). 1128–33. 2 indexed citations

14.

Gillies, Stephen D., Yan Lan, Thore Hettmann, et al.. (2011). A Low-Toxicity IL-2–Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity. Clinical Cancer Research. 17(11). 3673–3685. 77 indexed citations

15.

Davis, Jonathan H., Christel Aperlo, Yue Li, et al.. (2010). SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies†. Protein Engineering Design and Selection. 23(4). 195–202. 153 indexed citations

16.

Segreti, Jason A., Kennan C. Marsh, Joy Bauch, et al.. (2010). Tumour‐selective antivascular effects of the novel anti‐mitotic compound A‐318315: Anin vivorat regional haemodynamic study. Clinical and Experimental Pharmacology and Physiology. 37(5-6). 636–640. 3 indexed citations

17.

Gillies, Stephen D., Yan Lan, Steven A. Williams, et al.. (2005). An anti-CD20–IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. Blood. 105(10). 3972–3978. 77 indexed citations

18.

Way, Jeffrey C., Scott Lauder, Beatrice Brunkhorst, et al.. (2005). Improvement of Fc–erythropoietin structure and pharmacokinetics by modification at a disulfide bond. Protein Engineering Design and Selection. 18(3). 111–118. 28 indexed citations

19.

Gillies, Stephen D., et al.. (2002). Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer. Cancer Immunology Immunotherapy. 51(8). 449–460. 60 indexed citations

20.

Lo, Kin-Ming, et al.. (1998). High level expression and secretion of Fc-X fusion proteins in mammalian cells. Protein Engineering Design and Selection. 11(6). 495–500. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact